VELA Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

VELA Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,818	Closed	-$348K	–	162
2023 Q4	$348K	Sell	1,818 -1,599	-47%	-$272K	0.13%	141
2023 Q3	$605K	Hold	3,417	–	–	0.27%	100
2023 Q2	$649K	Hold	3,417	–	–	0.3%	96
2023 Q1	$684K	Buy	3,417 +92	+3%	+$19.3K	0.31%	94
2022 Q4	$790K	Hold	3,325	–	–	0.39%	81
2022 Q3	$666K	Buy	3,325 +350	+12%	+$66.8K	0.38%	79
2022 Q2	$434K	Hold	2,975	–	–	0.25%	104
2022 Q1	$486K	Buy	2,975 +544	+22%	+$82.9K	0.31%	93
2021 Q4	$412K	Buy	+2,431	New	+$452K	0.28%	103

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

VELA Investment Management's ALNY Position: Q1 2024 in Review

VELA Investment Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2024, closing a stake of 1,818 shares — an estimated $348K sold.

VELA Investment Management first reported a position in ALNY in Q4 2021 and held it in 9 quarters. The position peaked at $790K in Q4 2022. 499 funds tracked by Wall St. Rank hold ALNY as of Q1 2024.

VELA Investment Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
VELA Investment Management sold 1,818 Alnylam Pharmaceuticals shares in Q1 2024, an estimated $348K.
VELA Investment Management first reported a position in Alnylam Pharmaceuticals in Q4 2021 and held it in 9 quarters.
VELA Investment Management's Alnylam Pharmaceuticals position peaked at $790K in Q4 2022.
499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2024.

Based on VELA Investment Management's 13F filing for Q1 2024, filed 13 May 2024.